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AbsTrACT
Objectives spontaneous clearance of Chlamydia 
trachomatis (cT) infections can occur between diagnosis 
and treatment. We followed cT patients to assess clearance 
using a conventional definition (no total cT- Dna, assessed 
by routine quantitative Pcr methods) and a definition 
accounting for viability, assessed by viability Pcr testing.
Methods Three outpatient sTi clinics included cT- 
diagnosed women (The netherlands, 2016–2017, Femcure 
study); participants had vaginal cT (vcT) and rectal cT 
(rcT) (group a: n=155), vcT and were rectally untested 
(group B: n=351), single vcT (group c: n=25) or single 
rcT (group D: n=29). Follow- up (median interval 9 days) 
vaginal and rectal samples underwent quantitative Pcr 
testing (detecting total cT- Dna). When Pcr positive, 
samples underwent V- Pcr testing to detect ’viable cT’ 
(cT- Dna from intact cT organisms; V- Pcr positive). 
’clearance’ was the proportion Pcr- negative patients and 
’clearance of viable cT’ was the proportion of patients 
testing Pcr negative or Pcr positive but V- Pcr negative. 
We used multivariable logistic regression analyses to 
assess diagnosis group (a–D), age, days since initial cT test 
(diagnosis) and study site (sTi clinic) in relation to clearance 
and clearance of viable cT.
results clearance and clearance of viable cT at both 
anatomic sites were for (a) 0.6% and 3.9%; (B) 5.4% 
and 9.4%; (c) 32.0% and 52.0% and (D) 27.6% and 
41.4%, respectively. in multivariate analyses, women 
with single infections (groups c and D) had higher 
likelihood of clearance than women concurrently 
infected with vcT and rcT (p<0.001).
Of rectally untested women (group B), 76.9% had total 
cT- Dna and 46.7% had viable cT (V- Pcr positive) at 
the rectal site.
Conclusions Of untreated female vcT patients who had 
cT also at the rectal site, or who were rectally untested, 
only a small proportion cleared cT (in fact many had viable 
cT) at their follow- up visit (median 9 days). among single 
site infected women clearance was much higher.
Trial registration number ncT02694497.
InTrOduCTIOn
Chlamydia trachomatis (CT) infection is the most 
commonly reported treatable bacterial STI in high- 
income countries, with over 100 million people 
affected each year.1 2 CT disproportionally affects 
women in terms of its occurrence and burden of 
sequelae, including pelvic inflammatory disease, 
ectopic pregnancy, tubal infertility and chronic 
abdominal pain.3–5 However, spontaneous clear-
ance of urogenital CT has been reported,6 between 
19%–54% within 1 year7 8 and 6%–44% between 
diagnosis and treatment,9–13 using quantitative PCR 
tests (or nucleic acid amplification tests (NAATs)). 
Studies on rectal clearance are scarce, reporting 
18.2% in men and women (2/11; median interval 11 
days)14 and 4.0% (1/25) in men and 18.4% (7/38) in 
women (median interval 8 days).13 Research demon-
strated lower CT bacterial load as the only determi-
nant for clearance.13
The highly sensitive assays that are widely used 
for diagnosing CT detect both CT- DNA from intact 
CT organisms (indicative of viable CT) and CT- DNA 
from non- viable CT (eg, nucleic acid remnants). As 
current tests are unable to distinguish viable from non- 
viable organisms, a positive result may reflect non- 
viable CT. Hence, we may propose another definition 
of clearance to the detection of viable CT only (ie, to 
consider clearance having occurred when there is no 
more viable CT and ignore remnant bacterial DNA). 
Recently, we validated a PCR method for assessment 
of CT viability (V- PCR) in clinical swab samples.15 16 
This method combines the high sensitivity and spec-
ificity of PCR with the ability to exclude detection 
of nucleic acid remnants from non- viable CT. It does 
so by incorporating a sample pretreatment step with 
a membrane impermeable DNA intercalating dye 
prior to molecular analysis blocking amplification 
of remnant CT- DNA from non- viable bacteria. This 
allows the V- PCR analyses to detect CT- DNA orig-
inating from intact (ie, viable) bacteria. Assessment 
of CT viability as well as evaluating both the vaginal 
and rectal site is vital to fill the current knowledge 
gaps regarding spontaneous CT clearance in women. 
Here, we assessed clearance of total CT- DNA and of 
viable CT in women diagnosed with rectal CT (rCT) 
or vaginal CT (vCT) (FemCure)17 when they returned 
to the clinic for treatment.
MeThOds
regular care sTI clinic setting
The study population consisted of participants of 
the FemCure study,17 recruited at the STI clinics 
of the Public Health Services South Limburg, 
Rotterdam- Rijnmond and Amsterdam. The STI 
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clinics apply the same procedures, using different NAATs with 
similar high sensitivity18 (Limburg: Roche Cobas 4800, CT/NG 
PCR assay (Roche Diagnostics, Basel, Switzerland); Amsterdam: 
Aptima combo 2 CT/NG TMA assay (Hologic Inc, San Diego, 
USA); and Rotterdam- Rijnmond: ProbeTec CT/NG SDA assay 
(BectonDickinson, Franklin Lakes, USA)). All women were 
tested for vaginal CT. Women were also tested rectally if they 
reported anal sex or anal symptoms.19 At follow- up, women 
with a positive rectal result were treated with a 7- day course of 
oral doxycycline 100 mg twice daily.19 Women who were vagi-
nally positive and either not rectally tested or rectally negative 
received a 1 g single oral dose of azithromycin.
study population
Women who were diagnosed with a vaginal or a rectal CT infec-
tion (April 2016–September 2017) were included when they 
returned to the clinic for treatment (here called: follow- up visit). 
Inclusion criteria were age 18 years and older; negative for HIV, 
syphilis and Neisseria gonorrhoeae; no antibiotic use in the past 
month; and not being pregnant.17
Participants were categorised into diagnosis groups based on 
their initial STI clinic diagnosis: (A) vCT and rCT positive, (B) 
vCT positive and rCT untested, (C) vCT positive and rCT nega-
tive and (D) vCT negative and rCT positive.
Follow-up visit: CT-dnA and viable CT testing
Participants self- collected samples (swabs) first at the rectal site 
and then at the vaginal site just prior to antibiotic treatment. 
These samples were analysed for the current report.
For each anatomic site, a first sample was collected for viability 
testing, and a second sample was collected for CT- DNA testing. 
The sample for viability testing was placed in 4 mL sucrose phos-
phate (2SP) transport buffer and immediately stored at −80°C 
to maintain CT viability until laboratory analysis. The sample for 
CT- DNA testing was placed in COBAS buffer and used to test 
for total CT- DNA with PCR (Roche Cobas 4800), according to 
manufacturers’ guidelines. Of the women who tested positive in 
PCR (ie, when total CT- DNA was detected), samples were subse-
quently tested for viability with V- PCR. A positive V- PCR test 
indicates presence of CT- DNA from intact (viable) CT organ-
isms; a negative V- PCR test indicates that CT- DNA from intact 
(viable) CT organisms was not detected (thus indicates presence 
of remnant CT- DNA (non- viable CT) only).15 17
definitions of clearance
Clearance was defined as a sample testing negative by PCR (no 
total CT- DNA).
Clearance of viable CT was defined as a sample testing either 
negative by PCR or testing positive by PCR but negative by 
V- PCR (non- viable CT only).
It should be noted that ‘clearance’ infers a transition from a 
positive status (a diagnosis at first visit) to a negative status (at 
follow- up, just prior to treatment). We acknowledge that the CT 
positive status was not confirmed in all women as in group B, 
rCT was untested. Also viable CT status was unknown at diag-
nosis as viability testing was not possible on the type of swabs 
collected in routine care. ‘Clearance’ is used throughout for ease 
of reading and clarified to address the above limitation when 
needed.
statistical analyses
First, we present clearance proportions at the level of anatom-
ical site (infection level). Second, we present proportions at 
patient level and separately for the diagnosis groups A–D, as 
these groups internationally reflect common STI clinic testing 
practices. We used univariable and multivariable logistic regres-
sion to evaluate the independent association between clearance 
outcomes and diagnosis group (A–D), age, time since initial STI 
clinic test (categories based on tertiles), study site (STI clinic) 
and self- reported history of CT, considering an overall p value 
of p<0.05 as statistically significant (and between 0.05 and 0.07 
as borderline significant). We also presented univariable analyses 
for education, background and number of sex partners in the 
last 3 months.17 We used IBM SPSS Statistics V.24 for analyses.
resulTs
study population
In total, 560 women participated in the FemCure study. Based on 
the diagnostic (first) clinic visit, 531 women had vCT (ie, groups 
A, B and C), and 184 women had rCT (ie, groups A and D). 
Group A had 155 women with vCT and concurrent rCT, group 
B had 351 women with vCT and who were rCT untested, group 
C had 25 women with single vCT (rCT negative) and group D 
had 29 women with single rCT (vCT negative) (online supple-
mentary table 1). Median age was 22 years, that is, for groups 
A: 23 years (IQR 21–25], group B: 22 years (IQR 20–24), group 
C: 24 years (IQR 21–25) and group D: 25 years (IQR 22–28).
Women returned for follow- up after a median of 9 days, that 
is, for group A: 10 days (IQR 8–13), group B: 8 days (IQR 7–11), 
group C: 10 days (IQR 8–14) and group D: 10 days (IQR 8–13).
Clearance of vCT in 531 vCT diagnosed women (infection 
level)
Clearance was 6.0% (95% CI 4.2 to 8.4) and clearance of 
viable CT was 11.7% (95% CI 9.1 to 14.7). In multivariable 
logistic regression, clearance was higher in vCT single infected 
women (group C), compared with women with concurrent rCT 
(group A), and in participants at the Rotterdam- Rijnmond clinic, 
compared with the Limburg clinic. Clearance of viable CT was 
higher in single vCT infected women (group C), in women aged 
21–23 or 24 years and older, compared with women 18–20 years 
and (borderline significantly higher) in women with a history of 
CT (table 1).
Clearance of rCT in 184 rCT diagnosed women (infection 
level)
Clearance was 15.8% (95% CI 10.8 to 21.8) and clearance of 
viable CT was 35.9% (95% CI 28.9 to 43.3). Clearance was 
borderline significantly higher in women with single rCT (group 
D) compared with women with concurrent vCT (group A) and 
in women with a history of CT (table 2).
Clearance at both anatomic sites in 560 vCT or rCT diagnosed 
women (patient level)
Clearance was 6.4% (95%CI:4.5 to 8.8) and clearance of viable 
CT was 11.4% (95%CI:8.9 to 14.4). In multivariable logistic 
regression, proportions of both outcomes were higher in rectally 
untested patients (group B), and substantially higher in vCT 
or rCT single infected women (groups C, D). Clearance was 
also higher in participants at the Rotterdam- Rijnmond clinic, 
compared with the Limburg clinic. Clearance of viable CT was 
higher in groups B,C, and D (compared with group A) and in 
women aged 21–23 years or 24 years and older (compared with 
18–20 years) (table 3).
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Table 1 Proportions and odds ratios of clearance of total CT- DNA and clearance of viable CT at the vaginal site in 531 women who were 
diagnosed with vCT (FemCure)
Clearance of total CT- dnA Clearance of viable CT
n/n (%) Or (95% CI) aOr (95% CI) n/n (%) Or (95% CI) aOr (95% CI)
Total 32/531 (6.0) 62/531 (11.7)
Diagnosis group
  (A) vCT and rCT 3/155 (1.9) 1*** 1*** 10/155 (6.5) 1*** 1***
  (B) vCT (rCT not tested) 21/351 (6.0) 2.22 (0.95 to 10.98) 3.35 (0.93 to 12.04) 39/351 (11.1) 1.81 (0.88 to 3.73) 2.14 (0.99 to 4.62)
  (C) vCT (rCT negative) 8/25 (32.0) 23.84 (5.77 to 98.49) 21.81 (4.94 to 96.27) 13/25 (52.0) 15.71 (5.70 to 43.26) 15.63 (5.37 to 45.51)
Years of age
  18–20 7/159 (4.4) 1 1 9/159 (5.7) 1* 1*
  21–23 10/197 (5.1) 1.16 (0.43 to 3.12) 1.20 (0.43 to 3.37) 28/197 (14.2) 2.76 (1.26 to 6.04) 2.79 (1.24 to 6.30)
  ≥24 15/175 (8.6) 2.04 (0.81 to 5.13) 1.78 (0.66 to 4.78) 25/175 (14.3) 2.78 (1.26 to 6.15) 2.47 (1.07 to 5.70)
Days since initial CT diagnosis
  1–7 11/200 (5.5) 1 1 22/200 (11.0) 1 1
  8–11 12/194 (6.2) 1.13 (0.49 to 2.63) 1.22 (0.50 to 2.97) 21/194 (10.8) 0.98 (0.52 to 1.85) 0.97 (0.49 to 1.90)
  ≥12 9/137 (6.6) 1.21 (0.49 to 3.00) 1.42 (0.52 to 3.91) 19/137 (13.9) 1.30 (0.68 to 2.51) 1.31 (0.63 to 2.73)
Study site (STI clinic)
  Limburg 6/188 (3.2) 1* 1* 17/188 (9.0) 1 1
  Rotterdam- Rijnmond 17/160 (10.6) 3.61 (1.39 to 9.38) 3.71 (1.33 to 10.33) 22/160 (13.8) 1.60 (0.82 to 3.14) 1.60 (0.77 to 3.22)
  Amsterdam 9/183 (4.9) 1.57 (0.55 to 4.50) 1.78 (0.58 to 5.48) 23/183 (12.6) 1.45 (0.75 to 0.81) 1.49 (0.71 to 3.10)
Self- reported history of CT
  Yes 15/151 (9.9) 2.36 (1.44 to 4.85) 1.55 (0.70 to 3.42) 28/151 (18.5) 2.32 (1.34 to 4.00) 1.74 (0.96 to 3.15)
  No† 17/380 (4.5) 1** 1 34/380 (8.9) 1** 1‡
Education
  Low 16/195 (8.2) 1 na 28/195 (14.4) 1‡ na
  Middle† 8/197 (4.1) 0.42 (0.17 to 1.02) 20/197 (10.2) 0.57 (0.29 to 1.12)
  High 8/139 (5.8) 0.77 (0.32 to 1.85) 14/139 (10.1) 1.13 (0.58 to 2.22)
Background
  Western 27/489 (5.5) 1 na 54/489 (11.0) 1 na
  Non- Western 5/42 (11.9) 2.31 (0.84 to 6.36) 8/42 (19.0) 1.90 (0.83 to 4.31)
No. of sex partners last 3 months na
  0 or 1 15/186 (8.1) 1 21/186 (11.3) 1 na
  2 or 3 13/257 (5.1) 0.61 (0.28 to 1.31) 29/57 (11.3) 1.00 (0.55 to 1.84)
  ≥4 4/88 (4.5) 0.54 (0.18 to 1.69) 12/88 (13.6) 1.24 (0.58 to 2.65)
Clearance of total CT- DNA: at follow- up, no total CT- DNA detected at the vaginal site; clearance of viable CT: at follow- up, no total CT- DNA or only non- viable CT at the vaginal 
site.
*Overall p value 0.01 to <0.05, **overall p value 0.001 to <0.01, ***overall p value <0.001.
†The few cases with unknown information are attributed to this category in analyses.
‡Overall p value 0.05 to <0.07.
This model includes diagnosisgroup, age, days since initial CT test (diagnosis), and study site (STI clinic);CI: Confidence interval; viability polymerase chain reaction (V- PCR) is 
used totest for viable CT; na: variable not entered into the multivariable model to calculateadjusted odds ratio.
aOR, OR in the multivariable analyses; CT, Chlamydia trachomatis; OR, odds ratio in univariable analyses; rCT, rectal Chlamydia trachomatis; vCT, vaginal Chlamydia trachomatis.
distribution of test results at follow-up (patient level)
While some women cleared total CT- DNA (see above), most 
women tested PCR positive at follow- up, and many tested 
V- PCR positive (indicating viable infections) (table 4). The 
proportion of vCT diagnosed women testing V- PCR positive at 
both the vaginal and rectal site at follow- up was 62.6% in group 
A (concurrent rCT) and 46.7% in group B (rectally untested). Of 
single vCT diagnosed women (rCT negative, group C), 36.0% 
(9/25) women rectally had CT- DNA at follow- up (two had 
viable CT).
dIsCussIOn
In untreated women with a vaginal or rectal CT diagnosis 
visiting STI clinics, we assessed the spontaneous clearance on 
their follow- up visit for treatment (after a median of 9 days), 
using a conventional definition (no total CT- DNA) and a defi-
nition accounting for viability (no CT- DNA or only remnant 
CT- DNA (non- viable CT)). This is the first prospective study in a 
large group of women evaluating both anatomic sites within the 
same patient and including viability testing. We demonstrated 
low proportions of clearance in vCT patients who had a concur-
rent rCT diagnosis or who were rectally untested. This was in 
contrast to proven single site infected women of whom many 
showed clearance. Almost half of women who were rectally 
untested in regular STI clinic care showed viable CT at the rectal 
site at the follow- up visit.
The clearance of CT- DNA at the vaginal site (6.0% in vCT 
diagnosed women; groups A, B and C) or at the rectal site (15.8% 
in rCT diagnosed women; groups B and D) is comparable with 
previous studies.6–14 Employing the definition of clearance of 
viable organism data increased proportions to 11.7% for the 
vaginal site and 39.5% for the rectal site. The higher clear-
ance proportions observed at the rectal site (compared with the 
vaginal site) are notable. Possibly initial load at the rectal site is 
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Table 2 Proportions and odds ratios of clearance of total CT- DNA and clearance of viable CT at the rectal site in 184 women who were previously 
RCT diagnosed (FemCure)
Clearance of total CT- dnA Clearance of viable CT
n/n (%) Or (95% CI) aOr (95% CI) n/n (%) Or (95% CI) aOr (95% CI)
Total 29/184 (15.8) 66/184 (35.9)
Diagnosis group
  (A) vCT and rCT 21/155 (13.5) 1† 1† 54/155 (34.8) 1 1
  (C) vCT (rCT negative) 8/29 (27.6) 2.43 (0.95 to 6.19) 2.74 (0.97 to 7.70) 12/29 (41.4) 1.32 (0.59 to 2.97) 1.34 (0.57 to 3.19)
Years of age
  18–20 6/41 (14.6) 1 1 12/41 (29.3) 1 1
  21–23 10/63 (15.9) 1.10 (0.37 to 3.30) 1.14 (0.36 to 3.57) 25/63 (39.7) 1.59 (0.69 to 3.69) 1.67 (0.70 to 3.96)
  ≥24 13/80 (16.3) 1.13 (0.40 to 3.24) 0.96 (0.31 to 2.99) 29/80 (36.3) 1.37 (0.61 to 3.10) 1.31 (0.55 to 3.07)
Days since initial CT diagnosis
  1–7 7/43 (16.3) 1 1 16/43 (37.2) 1 1
  8–11 13/72 (18.1) 1.13 (0.41 to 3.11) 0.89 (0.30 to 2.65) 29/72 (40.3) 1.14 (0.52 to 2.48) 0.91 (0.40 to 2.06)
  ≥12 9/69 (13.0) 0.77 (0.26 to 2.25) 0.58 (0.18 to 1.89) 21/69 (30.4) 0.74 (0.33 to 1.65) 0.57 (0.24 to 1.35)
Study site (STI clinic)
  Limburg 3/46 (6.5) 1 1 12/46 (26.1) 1 1
  Rotterdam- Rijnmond 6/35 (17.1) 2.97 (0.69 to 18.82) 3.66 (0.79 to 16.99) 12/35 (34.3) 1.48 (0.57 to 3.86) 1.55 (0.57 to 4.17)
  Amsterdam 20/103 (19.4) 3.45 (0.97 to 12.28) 4.43 (1.16 to 16.91) 42/103 (40.8) 1.95 (0.91 to 4.20) 2.25 (1.00 to 5.06)
Self- reported history of CT
  Yes 15/59 (25.4) 2.70 (1.21 to 6.06) 2.41 (1.04 to 5.60) 26/59 (44.1) 1.67 (0.89 to 3.17) 1.57 (0.81 to 3.04)
  No‡ 14/125 (11.2) 1* 1* 40/125 (32.0) 1 1
Education
  Low 8/57 (14.0) 1 na 20/57 (35.1) 1 na
  Middle‡ 13/62 (21.0) 1.63 (0.62 to 4.27) 25/62 (40.3) 1.25 (0.59 to 2.63)
  High 8/65 (12.3) 0.86 (0.30 to 2.46) 21/65 (32.3) 0.88 (0.42 to 1.87)
Background
  Western 28/171 (16.4) 1 na 62/171 (36.3) 1 na
  Non- Western 1/13 (7.7) 0.43 (0.05 to 3.41) 4/13 (30.8) 0.78 (0.23 to 2.64)
No. of sex partners last 3 months
  0 or 1 10/57 (17.5) 1 na 15/57 (26.3) 1 na
  2 or 3 15/88 (17.0) 0.97 (0.40 to 2.33) 38/88 (43.2) 2.13 (1.03 to 4.39)
  ≥4 4/39 (10.3) 0.54 (0.16 to 1.86) 13/39 (33.3) 1.40 (0.58 to 3.41)
Clearance of total CT- DNA: at follow- up, no total CT- DNA detected at the rectal site; clearance of viable CT: at follow- up, no total CT- DNA or only non- viable CT at the rectal site.
This model includes diagnosis group, age, days since initial CT test (diagnosis) and study site (STI clinic); viability polymerase chain reaction is used to test for viable CT; na (variable not entered 
into the multivariable model to calculate adjusted ORs).
*Overall p value 0.01 to <0.05, **overall p value 0.001 to <0.01, ***overall p value <0.001.
†Overall p value 0.05 to <0.07.
‡The few cases with unknown information are attributed to this category in analyses.
aOR, OR in the multivariable analyses; CI, Confidence Interval; CT, Chlamydia trachomatis; OR, OR in univariable analyses; rCT, rectal Chlamydia trachomatis; vCT, vaginal Chlamydia trachomatis.
lower, or mucosal lining cells are less susceptible to CT infection 
than vaginal mucosal cells.20 21
At the patient level, clearance (at both anatomic sites) was low 
in vCT- diagnosed women who had concurrent rCT (clearance: 
0.6%, clearance of viable CT: 3.9%). Clearance was also low in 
vCT- diagnosed women who were rCT untested (5.4%, 9.3%).22 
Single vCT- infected (tested rCT negative) women, however, 
showed 32% clearance and 52% clearance of viable CT. It may 
be hypothesised that a diagnosed rCT is a marker for high viable 
CT loads at the vaginal site, when we assume that high vaginal 
CT loads are less likely to clear (as found previously13) and more 
likely to infect the rectal site (autoinoculation). Conversely, 
testing rCT negative would be a proxy for lower viable vaginal 
CT loads at diagnosis, with a higher likelihood of subsequent 
vaginal clearance. Unfortunately, we could not test this hypoth-
esis as we did not have data on (viable) loads at diagnosis. Of 
note, two observations in our study (table 4) suggest autoinoc-
ulation from the vaginal to the rectal site: (1) viable CT at the 
rectal site was almost always observed in the copresence of viable 
CT at the vaginal site. (2) Of the 25 rCT negative and vCT posi-
tive patients (group C), 9 became rCT positive (6/9 reported no 
recent anal sex), although this observation may also hint at the 
oral sex hypothesis.22 23
Furthermore, age of 21–23 years or 24 years and older 
(compared with 18–20) and history of CT were independently 
associated with clearance of viable infections. These findings 
may reflect protective immunity that developed from repeated 
chlamydia exposures.11 Finally, clearance proportions of vaginal 
total CT- DNA differed between study clinics, possibly explained 
by the different diagnostic NAAT tests used. Still, we consider 
this explanation unlikely as all used routine NAATs are highly 
sensitive and as STI clinics used the same NAAT for vaginal and 
rectal CT diagnostics (only differences in vaginal clearance were 
observed). Another unlikely explanation may be that clinics’ 
served populations differed regarding their mean initial vaginal 
CT- DNA loads (as low load is predictive for clearance). We 
could not study this as information on initial CT load at time of 
diagnosis was unavailable.
The potential clinical implications of this study are that in 
the majority of female patients, visiting STI clinics, with vCT 
and a concurrent or untested rCT, the likelihood of clearance 
(median interval 9 days) is low. Thus, the risk of overtreatment 
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Table 3 Proportions and ORs of clearance of total CT- DNA and clearance of viable CT at the vaginal and the rectal site in 560 women who were 
previously diagnosed with vCT or rCT in FemCure
Clearance of total CT- dnA Clearance of viable CT
n/n (%) Or (95% CI) aOr (95% CI) n/n (%) Or 95% CI aOr (95% CI)
  36/560 (6.4) 64/560 (11.4)
Diagnosis group
  (A) vCT and rCT 1/155 (0.6) 1*** 1*** 6/155 (3.9) 1*** 1***
  (B) vCT (rCT not tested) 19/351 (5.4) 8.81 (1.17 to 66.43) 8.52 (1.10 to 65.96) 33/351 (9.4) 2.58 (1.06 to 6.28) 2.80 (1.11 to 7.10)
  (C) vCT (rCT negative) 8/25 (32.0) 72.47 (8.54 to 614.95) 85.45 (9.49 to 769.34) 13/25 (52.0) 26.90 (8.67 to 83.46) 28.98 (8.83 to 95.12)
  (D) rCT (vCT negative) 8/29 (27.6) 58.67 (6.98 to 492.82) 72.22 (8.18 to 637.54) 12/29 (41.4) 17.53 (5.83 to 52.71) 17.07 (5.49 to 53.10)
Years of age
  18–20 7/162 (4.3) 1# 1 7/162 (4.3) 1** 1*
  21–23 10/204 (4.9) 1.14 (0.43 to 3.07) 1.11 (0.38 to 3.21) 26/204 (12.7) 3.23 (1.37 to 7.66) 3.36 (1.36 to 8.32)
  ≥24 19/194 (9.8) 2.40 (0.98 to 5.87) 1.58 (0.59 to 4.27) 31/194 (16.0) 4.21 (1.80 to 9.84) 3.20 (1.29 to 7.95)
Days since initial CT diagnosis
  1–7 12/207 (5.8) 1 1 23/207 (11.1) 1 1
  8–11 16/205 (7.8) 1.38 (0.63 to 2.99) 1.58 (0.68 to 3.69) 24/205 (11.7) 1.06 (0.58 to 1.95) 1.02 (0.52 to 1.99)
  ≥12 8/148 (5.4) 0.93 (0.37 to 2.33) 0.93 (0.32 to 2.69) 17/148 (11.5) 1.04 (0.53 to 2.02) 0.92 (0.42 to 2.00)
Study site (STI clinic)
  Limburg 6/199 (3.0) 1** 1** 17/199 (8.5) 1 1
  Rotterdam- Rijnmond 19/164 (11.6) 4.22 (1.64 to 10.82) 6.06 (2.13 to 17.25) 23/164 (14.0) 1.75 (0.90 to 3.39) 2.09 (0.99 to 4.40)
  Amsterdam 11/197 (5.6) 1.90 (0.69 to 5.25) 2.43 (0.81 to 7.29) 24/197 (12.2) 1.49 (0.77 to 2.86) 1.63 (0.78 to 3.42)
Self- reported history of CT
  Yes 15/165 (9.1) 1.78 (0.89 to 3.55) 0.95 (0.44 to 2.09) 28/165 (17.0) 2.04 (1.20 to 3.47) 1.33 (0.73 to 2.42)
  No‡ 21/395 (5.3) 1 1 36/395 (9.1) 1** 1
Education
  Low 16/203 (7.9) 1 na 29/203 (14.3) 1 na
  Middle‡ 11/208 (5.3) 0.65 (0.30 to 1.44) 18/208 (8.7) 0.57 (0.31 to 1.06)
  High 9/149 (6.0) 0.75 (0.32 to 1.75) 17/149 (11.4) 0.77 (0.41 to 1.47)
Background
  Western 31/57 (6.0) 1 na 57/517 (11.0) 1 na
  Non- Western 5/43 (11.6) 2.06 (0.76 to 5.61) 7/43 (16.3) 1.57 (0.67 to 3.69)
No. of sex partners last 3 months
  0 or 1 15/195 (7.7) 1 na 21/195 (10.8) 1 na
  2 or 3 17/269 (6.3) 0.81 (0.39 to 1.66) 31/269 (11.5) 1.08 (0.60 to 1.94)
  ≥4 4/96 (4.2) 0.52 (0.17 to 1.62) 12/96 (12.5) 1.18 (0.56 to 2.52)
Clearance of total CT- DNA: at follow no total CT- DNA detected at both anatomic sites; clearance of viable CT: at follow- up no total CT- DNA detected or only non- viable CT detected at both 
anatomic sites.
This model includes diagnosis group, age, days since initial CT test (diagnosis), and study site (STI clinic); viability polymerase chain reaction is used to test for viable CT; na (variable not entered 
into the multivariable model to calculate adjusted OR).
*Overall p value 0.01 to <0.05, **overall p value 0.001 to <0.01, ***overall p value <0.001.
†Overall pvalue 0.05 to <0.07.
‡The few cases with unknown information are attributed to this category in analyses.
aOR, odds ratio in the multivariable analyses; CI, Confidence Interval; CT, Chlamydia trachomatis; OR, OR in univariable analyses; rCT, rectal Chlamydia trachomatis; vCT, vaginal Chlamydia 
trachomatis.
will be very low. When one is interested to restrict treatment to 
viable infections only, the lower viable CT detection in single 
site CT- infected women and in those aged >20 years is notable, 
but these predictors lack specificity to guide treatment policy. 
Perhaps the most important direct implication for clinical prac-
tice can be derived from our finding that in rectally untested 
women (group B), 87.5% (n=272/351) had CT- DNA and 
48.4% (n=170/351) had viable rectal CT at follow- up (table 4). 
This is indicative of large numbers of missed (viable) rectal infec-
tions when women present for vaginal CT treatment. In clinical 
practice, most women remain rectally untested, missing two- 
thirds of rectal CT infections when diagnosing vCT.24 25 It may 
be a problem when these rectally untested (but rCT positive) 
women are treated with azithromycin for their vCT, as azith-
romycin is less effective than doxycycline for rCT.26 27 In some 
of the Dutch STI clinics, and in some international guidelines, 
universal doxycycline treatment for CT infections in women has 
been adopted, potentially tackling the aforementioned issue. It 
should be noted that clinical implications of CT- DNA and viable 
CT at the rectal site (in terms of ‘true infections’, transmission- 
potential, morbidity) are yet unknown, and we also do not know 
whether the clinical impact of rectal infections would be affected 
by the underlying route of infection (eg, autoinoculation).
This study has several limitations. (1) We did not have infor-
mation on viable CT at time of initial diagnosis. V- PCR anal-
yses is not possible on routinely collected materials as it requires 
a specific transport buffer and immediate storage in −80°C, 
precluding the assessment of viability in current routine clin-
ical care diagnosis. Therefore, as in all clearance studies, the 
starting point was CT diagnosis by regular care tests (assessing 
total CT- DNA). Thus, the observed proportions of non- viable 
CT may be an overestimation when interpreted as the transition 
from viable to non- viable. (2) As in all human clearance studies, 
the moment of infection is unknown. To aid interpretation, 
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Table 4 Distribution of CT- DNA and viable CT at the vaginal and the rectal site at the follow- up visit (just prior to treatment) a median of 9 days 
later, in 560 women who were previously CT diagnosed (FemCure)
Group A Group b Group C Group d
vCT and rCT vCT (rCT untested) vCT (rCT negative) rCT (vCT negative)
n=155, n (%) n=351, n (%) n=25, n (%) n=29, n (%)
CT- DNA (PCR positive) at follow- up
  No CT- DNA at vaginal and rectal site 1 (0.6) 19 (5.4) 8 (32.0) 8 (27.6)
  CT- DNA detected at the vaginal site only 20 (12.9) 60 (17.1) 8 (32.0) 0 (0)
  CT- DNA detected at the rectal site only 2 (1.3) 2 (0.6)* 0 (0) 21 (72.4)
  CT- DNA detected at the vaginal and rectal site 132 (85.2) 270 (76.9)* 9 (36.0)† 0 (0)
Viable CT (PCR and V- PCR positive) at follow- up
  No CT- DNA or only non- viable CT at vaginal and rectal site 6 (3.9) 33 (9.4) 13 (52.0) 12 (41.4)
  CT- DNA and viable CT at the vaginal site only 48 (31.0) 148 (42.2) 10 (40.0) 0 (0)
  CT- DNA and viable CT at the rectal site only 4 (2.6) 6 (1.7)* 0 (0) 17 (58.6)
  CT- DNA and viable CT at the vaginal and rectal site 97 (62.6) 164 (46.7)* 2 (8.0)† 0 (0)
CT- DNA is assessed with a quantitative PCR; viable CT is assessed with a viability PCR.
*The rectal site was initially not tested, thus could be positive or negative. The fact that at follow- up (just prior to treatment), some women rectally had CT- DNA or viable CT- DNA 
suggests that in those women the rectal site was initially positive (350/351 patients reported no anal sex in 2 weeks prior to treatment).
†The rectal site was initially tested CT- DNA negative. The fact that at follow- up (just prior to treatment), women rectally had CT- DNA or viable CT- DNA suggests that new 
infections may have occurred at the rectal site between diagnosis and treatment (6/9 patients reported no anal sex in the 2 weeks prior to treatment).
rCT, rectal Chlamydia trachomatis; vCT, vaginal Chlamydia trachomatis.
Key messages
 ► In the understudied population of women (560 Chlamydia 
trachomatis (CT) diagnosed patients), we assessed 
spontaneous clearance (median follow- up of 9 days) of CT 
infections at the vaginal and the rectal site and including 
viability testing.
 ► Women infected with CT at a single anatomic site CT had the 
highest likelihood to clear CT- DNA and to clear viable CT.
 ► In vaginal CT diagnosed female patients, clearance is low 
when they also were concurrently diagnosed with rectal CT 
or when they were rectally untested; in fact these patients 
commonly showed viable CT at both anatomic sites at 
follow- up.
 ► These findings might have diagnostic and therapeutic 
implications for women tested for CT.
antibody detection could be useful to exclude individuals who 
were exposed to CT but who were not infected,28 and CT load 
at diagnosis could help to predict spontaneous clearance,13 but 
samples to collect such data were unavailable. (3) The exact day 
of clearance is unknown, as we did not collect daily samples. 
(4) Clearance may differ by genotype,29–31 but genotyping was 
not performed on the diagnosis study samples. (5) Genotyping 
would also be valuable to exclude reinfections by other geno-
types, as positive results at follow- up were classified as ‘not 
cleared’ or ‘viable’ in this study. (6) Possibly, some initial test- 
positive results might be false positive. Also, using a single sensi-
tive PCR test to assess clearance could have resulted in detecting 
false positives or false negatives.32 ‘On off effects’, that is, a posi-
tive and negative test result in the same sample, might occur in 
samples with a low bacterial load around the detection limit. 
Related to this is the possibility of the initial test not being a ‘true 
infection’, but rather reflecting transient CT- DNA. This is also 
referred to as ‘passive infection’.33 34 We could not determine to 
what extent such a phenomenon was present in our STI clinics 
population and to what extent it may have affected our results. 
Furthermore, we could not estimate the duration of infection as, 
at diagnosis, the date of last sex (ie, exposure) was unknown. (7) 
The women sampled first the swab for V- PCR testing, and second 
the swab for PCR testing. In theory, the second swab may have 
had a lower bacterial load affecting clearance rates. However, we 
feel that such risk is minimal as the PCR test for CT- DNA test is 
highly sensitive. (8) We cannot entirely rule out contamination 
of swabs during sampling, for example, contamination of a rectal 
swab with vaginal secretions, despite clear written and visual 
instructions. (9) In the FemCure study sample, women with 
high education, without a previous STI or non- Western migrant 
background were under- represented compared with CT infected 
STI clinic women.27 However, these characteristics were not 
associated with clearance overall, and therefore, we think that 
these differences do not impact the internal validity of the study. 
(10) Our study population was confined by exclusion criteria, 
such as <18 years or STI coinfection, so inferences to excluded 
subsets are not possible. (11) Caution should be taken when 
making population inferences from the frequency distributions 
of FemCure’s baseline characteristics, as STI clinic populations 
may change over time due to policy changes. However, this may 
not be a substantial problem as we examined diagnosis groups, 
based on current testing practice. Lastly, STI clinic populations 
may not represent the general population.
To conclude, spontaneous clearance occurs at the vaginal and 
the rectal site and is more likely in women infected with CT at 
a single anatomic site. However, clearance is low in vCT diag-
nosed female patients who were concurrently diagnosed with 
rCT or were rCT untested. In fact, these patients commonly 
showed viable CT at the follow- up visit. These findings might 
have diagnostic and therapeutic implications for women tested 
for CT.
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